The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant buzz within the United Kingdom , prompting a notable shift in hormone trends. Access these compounds remains a complex landscape, with public healthcare system provision currently limited and independent providers offering therapy at a premium . Q